Defining new paradigms for the treatment of pancreatic cancer

Current Treatment Options in Oncology

Volumn 12, Issue 2, 2011, Pages 111-125

  Almhanna, Khaldoun ^a   Philip, Philip A ^b,c  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c 4 HWCRC ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; AFLIBERCEPT; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CANCER VACCINE; CAPECITABINE; CETUXIMAB; CIXUTUMUMAB; CONATUMUMAB; DALOTUZUMAB; DOCETAXEL; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GANITUMAB; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IPI 926; IRINOTECAN; LAROTAXEL; NC 6004; OXALIPLATIN; PACLITAXEL; PLACEBO; PROTEIN P53; RUBITECAN; SARACATINIB; SORAFENIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER STEM CELL; CARCINOGENESIS; CLINICAL TRIAL (TOPIC); DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG TOLERABILITY; DRUG TUMOR LEVEL; DRUG UPTAKE; HUMAN; INFUSION RELATED REACTION; MOLECULARLY TARGETED THERAPY; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS SURGERY; PROGRESSION FREE SURVIVAL; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TUMOR IMMUNITY; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANTINEOPLASTIC AGENTS; HUMANS; IMMUNE SYSTEM; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 79958033195     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-011-0150-8     Document Type: Article

References (59)

1. A Jemal R Siegel E Ward, et al. 2007 Cancer statistics, 2007 CA Cancer J Clin 57 1 43 66 17237035 10.3322/canjclin.57.1.43 (Pubitemid 46148091)
2. HA Burris 3rd MJ Moore J Andersen, et al. 1997 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 6 2403 13 9196156 1:CAS:528:DyaK2sXlsFKksLY%3D (Pubitemid 27251144)
3. D Cunningham I Chau D Stocken, et al. 2005 Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer (abstract) Eur J Cancer 3 4 abstract PS11
4. R Herrmann G Bodoky T Ruhstaller, et al. 2007 Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss group for clinical cancer research and the central European cooperative oncology group J Clin Oncol 25 16 2212 7 17538165 10.1200/JCO.2006.09.0886 1:CAS:528:DC%2BD2sXnsVShtbw%3D (Pubitemid 46954645)
5. MJ Moore D Goldstein J Hamm, et al. 2007 Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada clinical trials group J Clin Oncol 25 15 1960 6 17452677 10.1200/JCO.2006.07.9525 1:CAS:528:DC%2BD2sXmvVWmsr0%3D (Pubitemid 46972777)
6. D Von Hoff R Ramanathan M Borad, et al. 2009 SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: a phase I/II study J Clin Oncol 27 15s 10.1200/JCO.2008.21.7695 (suppl; abstr 4525)
7. M Loehr G Bodoky U Fölsch, et al. 2009 Cationic liposomal paclitaxel in combination with gemcitabine in patients with advanced pancreatic cancer: a phase II trial J Clin Oncol 27 15s 10.1200/JCO.2008.21.7695 (suppl; abstr 4526)
8. Ychou M, Desseigne F, Guimbaud R, et. al. Randomized phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma. First results of the ACCORD 11 trial. J Clin Oncol. 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 4516.
9. T Conroy F Desseigne M Ychou, et al. 2010 Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial J Clin Oncol 28 15s This study might change the standards of care for patients with metastatic pancreas cancer.
10. S Jones X Zhang DW Parsons JC Lin, et al. 2008 Core signaling pathways in human pancreatic cancers revealed by global genomic analyses Science 321 5897 1801 6 18772397 10.1126/science.1164368 1:CAS:528:DC%2BD1cXhtFCrtLrL Epub 2008 Sep 4
11. M Korc 2003 Pathways for aberrant angiogenesis in pancreatic cancer Mol Cancer 2 8 12556241 10.1186/1476-4598-2-8 1:STN:280:DC%2BD2czltlyhsA%3D%3D (Pubitemid 38751489)
12. AJ Karayiannakis H Bolanaki KN Syrigos, et al. 2003 Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis Cancer Lett 194 119 124 12706865 10.1016/S0304-3835(03)00047-8 1:CAS:528:DC%2BD3sXjtFCjsLg%3D (Pubitemid 36428891)
13. CJ Burns M Shrader MT Harbison, et al. 2002 Effect of the vascular endothelial growth factor receptor-2 antibody DC-101 plus gemcitabine on growth, metastasis, and angiogenesis of human pancreatic cancer growing orthotopically in nude mice Int J Cancer 102 101 108 10.1002/ijc.10681 (Pubitemid 35168021)
14. H Kindler G Friberg D Singh, et al. 2005 Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer J Clin Oncol 23 31 8033 8040 16258101 10.1200/JCO.2005.01.9661 1:CAS:528:DC%2BD2MXht1CqsL%2FE (Pubitemid 46657405)
15. Kindler H, Niedzwiecki D, Hollis D, et al. Cancer and Leukemia Group B. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB. J Clin Oncol. 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 4508.
16. E Van Cutsem WL Vervenne J Bennouna, et al. 2009 Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer J Clin Oncol 27 13 2231 7 19307500 10.1200/JCO.2008.20.0238 This study showed the lack of benefits of VGFR antibodies in the treatment of pancreatic cancer.
17. Mulay MS, Limentani A, Carroll M et al. Safety and pharmacokinetics of intravenous VEGF Trap plus FOLFOX4 in a combination phase I clinical trial of patients with advanced solid tumors. J Clin Oncol. 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2006;24, No 18S (June 20 Supplement): 13061.
18. JP Spano C Chodkiewicz J Maurel, et al. 2008 Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study Lancet 371 9630 2101 8 18514303 10.1016/S0140-6736(08)60661-3 1:CAS:528:DC%2BD1cXnsFGjurs%3D Epub 2008 May 29
19. C Gianpaolo-Ostravage C Carter B Hibner 2001 Anti-tumor efficacy of the orally active raf kinase inhibitor BAY 43-9006 in human tumor xenograft models Proc Am Assoc Cancer Res 42 923
20. Siu LL, Awada A et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res. 12:144-51
21. Wallace JA, Nattam S, et al.: 2007. Sorafenib plus gemcitabine for advanced pancreatic cancer: A phase II trial of the University of Chicago Phase II Consortium. J Clin Oncol. 2007 ASCO Ann Meeting Proc, 25(18S): 4608.
22. NR Lemoine CM Hughes, et al. 1992 The epidermal growth factor receptor in human pancreatic cancer J Pathol 166 7 12 1538276 10.1002/path.1711660103 1:STN:280:DyaK387ms12hsw%3D%3D
23. Y Yamanaka H Friess, et al. 1993 Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness Anticancer Res 13 565 9 8317885 1:STN:280: DyaK3szgsVyruw%3D%3D
24. CJ Bruns CC Solorzano MT Harbison, et al. 2000 Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma Cancer Res 60 2926 2935 10850439 1:CAS:528:DC%2BD3cXjvFOltrs%3D (Pubitemid 30395817)
25. SSW Ng MS Tsao T Nicklee, et al. 2002 Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma Mol Cancer Ther 1 777 783 12492110 1:CAS:528:DC%2BD3sXlslGkug%3D%3D
26. J Baselga CL Arterga 2005 Critical update and emerging trends in epidermal growth factor receptor targeting in cancer J Clin Oncol 23 11 2445 2459 15753456 10.1200/JCO.2005.11.890 1:CAS:528:DC%2BD2MXjvVykt7c%3D (Pubitemid 47050835)
27. PA Philip J Benedetti CL Corless, et al. 2010 Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial S0205 J Clin Oncol 28 22 3605 10, Epub 2010 Jul 6 20606093 10.1200/JCO.2009.25. 7550 1:CAS:528:DC%2BC3cXhtFSksb3O This study showed the lack of benefits of EGFR antibodies in the treatment of pancreatic cancer.
28. Blaszkowsky LS, Earle C et al. 2007. A phase II study of docetaxel in combination with ZD1839 (gefitinib) in previously treated patients with metastatic pancreatic cancer. J Clin Oncol. 2007 ASCO Ann Meeting Proc, 25(25 18S):15080.
29. Safran H, Miner K et al.: 2006. GW572016, gemcitabine and GW572016, gemcitabine, oxaliplatin, a two-stage, phase I study for advanced pancreaticobiliary cancer. J Clin Oncol. 2006 ASCO Ann Meeting Proc, 24(18S): 4002.
30. MN Pollak ES Schernhammer SE Hankinson 2004 Insulin-like growth factors and neoplasia Nat Rev Cancer 4 505 18 15229476 10.1038/nrc1387 1:CAS:528:DC%2BD2cXlt1Oktro%3D (Pubitemid 38868620)
31. L Goetsch A Gonzalez O Leger, et al. 2005 A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts Int J Cancer 113 316 28 15386423 10.1002/ijc.20543 1:CAS:528:DC%2BD2cXhtFajtb7P (Pubitemid 39628325)
32. A Camirand M Zakikhani F Young, et al. 2005 Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells Breast Cancer Res 7 R570 9 15987464 10.1186/bcr1028
33. H Kindler D Richards J Stephenson, et al. 2010 A placebo-controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC) J Clin Oncol 28 15s 10.1200/JCO.2010.28.1386 (suppl; abstr 4035)
34. MT Yip-Schneider CM Schmidt 2003 MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac Pancreas 27 4 337 44 14576498 10.1097/00006676-200311000-00012 1:CAS:528:DC%2BD2cXks1yjtA%3D%3D (Pubitemid 37337901)
35. J Rinehart A Adjei P LoRusso, et al. 2004 Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer J Clin Oncol 22 22 4456 4462 15483017 10.1200/JCO.2004.01.185 1:CAS:528:DC%2BD2cXhtFWqt77L (Pubitemid 41185111)
36. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol. 13:513-609.
37. RA Perugini TP McDade FJ Vittimberga Jr, et al. 2000 Pancreatic cancer cell proliferation is phosphatidylinositol 3-kinase dependent J Surg Res 90 39 44 10781373 10.1006/jsre.2000.5833 1:CAS:528:DC%2BD3cXis1Oqsro%3D (Pubitemid 30317175)
38. SSW Ng MS Tsa S Chow, et al. 2000 Inhibition phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells Cancer Res 60 5451 5455 11034087 1:CAS:528:DC%2BD3cXns1ehtrw%3D
39. JQ Cheng B Ruggeri WM Klein, et al. 1996 Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA Proc Natl Acad Sci USA 93 3636 3641 8622988 10.1073/pnas.93.8.3636 1:CAS:528:DyaK28XisVWiurs%3D (Pubitemid 26127592)
40. S Tanno S Tanno Y Mitsuuchi, et al. 2001 AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells Cancer Res 61 2 589 93 11212254 1:CAS:528:DC%2BD3MXht1GmsLk%3D (Pubitemid 32128619)
41. MA Bjornsti PJ Houghton 2004 The TOR pathway: a target for cancer therapy Nat Rev Cancer 4 335 348 15122205 10.1038/nrc1362 1:CAS:528: DC%2BD2cXjsFSlu7Y%3D (Pubitemid 38579480)
42. VM Bondar B Sweeney-Gotsch M Andreeff, et al. 2002 Inhibition of the phosphatidylinositol 3-kinase- AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo Mol Cancer Ther 1 989 997 12481421 1:CAS:528:DC%2BD3sXmtFaguw%3D%3D
43. CJ Bruns GE Koehl M Guba, et al. 2004 Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer Clin Cancer Res 10 2109 2119 15041732 10.1158/1078-0432.CCR- 03-0502 1:CAS:528:DC%2BD2cXisVGksrc%3D (Pubitemid 38375573)
44. T Asano Y Yao J Zhu, et al. 2005 The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation Biochem Biophys Res Commun 331 295 302 15845392 10.1016/j.bbrc.2005.03.166 1:CAS:528:DC%2BD2MXjsFCht7w%3D (Pubitemid 40545175)
45. B Wolpin A Hezel T Abrams, et al. 2009 Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer J Clin Oncol 27 2 193 198 19047305 10.1200/JCO.2008.18.9514 1:CAS:528:DC%2BD1MXhvVKrsbw%3D
46. Y Sato Y Nio MM Song, et al. 1997 p53 protein expression as prognostic factor in human pancreatic cancer Anticancer Res 17 2779 2788 9252715 1:CAS:528:DyaK2sXlsFajsbk%3D (Pubitemid 27352687)
47. Wolkersdorfer GW, Thiede C, Fischer R et al. Adenoviral p53 gene transfer and gemcitabine in three patients with liver metastases due to advanced pancreatic carcinoma, HPB (Oxford). 2007;9: 16-25
48. AS Azmi A Aboukameel S Banerjee, et al. 2010 MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function Eur J Cancer 46 6 1122 31 20156675 10.1016/j.ejca.2010.01.015 1:CAS:528:DC%2BC3cXjs1altLw%3D Epub 2010 Feb 13
49. JM Plate JE Harris 2000 Immune cell functions in pancreatic cancer Crit Rev Immunol 20 375 11145216 1:CAS:528:DC%2BD3MXisVCjsg%3D%3D
50. EM Jaffee RH Hruban B Biedrzycki, et al. 2001 Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation J Clin Oncol 19 1 145 56 11134207 1:CAS:528:DC%2BD3MXot1WgtQ%3D%3D (Pubitemid 32063491)
51. D Laheru E Lutz J Burke, et al. 2008 Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation Clin Cancer Res 14 5 1455 18316569 10.1158/1078-0432.CCR-07-0371 1:CAS:528:DC%2BD1cXislSrsLk%3D (Pubitemid 351413929)
52. AN Shah JM Summy J Zhang, et al. 2007 Development and characterization of gemcitabine-resistant pancreatic tumor cells Ann Surg Oncol 14 3629 3637 17909916 10.1245/s10434-007-9583-5 (Pubitemid 350160137)
53. PC Hermann SL Huber T Herrler, et al. 2007 Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer Cell Stem Cell 1 313 323 18371365 10.1016/j.stem.2007.06.002 1:CAS:528:DC%2BD2sXhtFagu7vN (Pubitemid 47355323)
54. C Lee J Dosch D Simeone 2008 Pancreatic cancer stem cells J Clin Oncol 26 17 2806 2812 18539958 10.1200/JCO.2008.16.6702
55. SK Mungamuri X Yang AD Thor, et al. 2006 Survival signaling by notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53 Cancer Res 66 4715 4724 16651424 10.1158/0008-5472.CAN-05-3830 1:CAS:528:DC%2BD28XjvF2ktr4%3D
56. OH Yilmaz R Valdez BK Theisen, et al. 2006 PTEN dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells Nature 441 475 482 16598206 10.1038/nature04703 1:CAS:528:DC%2BD28XkvVykurY%3D (Pubitemid 44050144)
57. RL Yauch SE Gould SJ Scales, et al. 2008 A paracrine requirement for hedgehog signalling in cancer Nature 455 7211 406 10 18754008 10.1038/nature07275 1:CAS:528:DC%2BD1cXhtFams7fP Epub 2008 Aug 27
58. K Olive M Jacobetz CJ Davidson, et al. 2009 Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer Science 324 5933 1457 61 19460966 10.1126/science.1171362 1:CAS:528:DC%2BD1MXntVSiu7Y%3D Epub 2009 May 21
59. PA Philip M Mooney D Jaffe, et al. 2009 Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment J Clin Oncol 27 33 5660 9, Epub 2009 Oct 26 19858397 10.1200/JCO.2009.21.9022 This is a good summary of the national cancer institute recommendation on clinical trials design in pancreatic cancer.